KZIA Kazia Therapeutics Limited
Kazia Therapeutics Limited (KZIA) has not yet scheduled its next earnings release.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Kazia Therapeutics Limited
Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia.
Sector
Healthcare
Industry
Biotechnology